Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REGN5837 and Odronextamab in Aggressive B-Cell Non-Hodgkin Lymphomas
NCT05685173Phase 1Recruiting
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Apr 2023
- Primary completion
- Feb 2029
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 5
01
Overview
Phase 1, open-label trial of REGN5837 in B-cell non-Hodgkin lymphoma (2 arms), sponsored by Regeneron Pharmaceuticals. Primary endpoints: Dose Limiting Toxicities at 21 days, Treatment-Emergent Adverse Events at 5 years and 3 more. Started Apr 2023; status: recruiting.
02
Drugs
REGN5837
03
Conditions
B-cell non-Hodgkin lymphoma
Beyond the preview
Go deeper on NCT05685173.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05685173.